House to Vote for Repeal of ACA’s ‘Cadillac Tax’
Despite strong bipartisan support for a repeal of the onerous excise tax on health benefits, its fate in the Senate remains unclear.
How Will Insurer-PBM Deals Affect Health Costs?
It may take awhile, but the recent mergers of health insurers and pharmacy benefits managers could meaningfully mitigate the costs of care.
Companies Plead for New Pharma Supply Model
The long-entrenched system of drug-manufacturer rebates has not adapted to changes in health-plan designs and labor-market trends.
After Another Cadillac Tax Delay, Now What?
With the tax perhaps unlikely to ever take effect, should companies still factor it into their benefits planning and strategies?
As core strategies for containing employee health-care costs diminish in effectiveness, companies need fresher approaches.
How to Rein In the Soaring Costs of Specialty Drugs
The 420-employer National Business Group on Health recommends public-policy changes relating to the proliferating category of specialty drugs.
Modify, Not Replace, the ACA: Corporate Health Leader
Save the good and revise the bad, says Brian Marcotte of the National Business Group on Health
Uncertainty Flares Again for Health Benefits
Following this week's elections, CFOs are again in the dark about the outlook for the cost, delivery, and quality of company-sponsored health care.
Specialty Drugs Drive Health Care Cost Trend
Health benefits costs are forecast to climb 5% next year, thanks in part to fast-rising prices for specialty pharmaceuticals.
New Cures for Health Costs
Innovative ways to engage employees offer hope for bringing health care spending under control.
Two-Year Delay for Obamacare’s Cadillac Tax Likely
A proposal to postpone the despised excise tax is an 11th-hour inclusion in the federal budget bill.